Archana Sasi, Sindhura Chitikela, Shuvadeep Ganguly, Bivas Biswas, Deepam Pushpam, Akash Kumar, Shah Alam Khan, Venkatesan Sampath Kumar, Shashank Sharad Kale, Ahitagni Biswas, Adarsh Barwad, Asit Ranjan Mridha, Sanjay Thulkar, Sameer Bakhshi
{"title":"Treatment outcomes in patients with Ewing sarcoma of the spine in a resource-challenged setting: 17-year experience from a single center in India.","authors":"Archana Sasi, Sindhura Chitikela, Shuvadeep Ganguly, Bivas Biswas, Deepam Pushpam, Akash Kumar, Shah Alam Khan, Venkatesan Sampath Kumar, Shashank Sharad Kale, Ahitagni Biswas, Adarsh Barwad, Asit Ranjan Mridha, Sanjay Thulkar, Sameer Bakhshi","doi":"10.1080/08880018.2023.2296949","DOIUrl":null,"url":null,"abstract":"<p><p>Ewing sarcoma (ES) of the spine is a rare childhood cancer with sparse literature on treatment outcomes. We aimed to describe survival outcomes and prognostic factors in patients with spinal ES treated at a single institute in a resource-challenged setting. We conducted a retrospective analysis of patients with spinal ES registered at a tertiary care oncology center between 2003-2019. Clinical patient data was retrieved from hospital records. Cox regression analysis was used to identify the association of baseline clinical parameters with event free survival (EFS) and overall survival (OS). A cohort of 85 patients was analyzed including 38 (45%) patients with metastatic disease. The median age was 15 years with 73% being male. Local therapy was administered in 62 (72.9%) patients with surgery alone in 8 (9.4%), radiotherapy alone in 36 (42.4%) and both in 18 (21.2%) patients. A higher proportion of males received local therapy than females (80.3% versus 59.1%; <i>p</i> = 0.049). The median EFS and OS were 20.1 and 28.6 months, respectively. On univariable analysis, age ≤ 15 years, female sex, serum albumin ≤3.5 g/dL and hemoglobin ≤11 g/dL were associated with inferior EFS while younger age, female sex, hypoalbuminemia and metastatic disease were associated with inferior OS. On multivariable analysis, only hypoalbuminemia was predictive for inferior EFS (HR:2.41; <i>p</i> = 0.005) while hypoalbuminemia (HR:2.06;<i>p</i> = 0.033) and female sex (HR:1.83; <i>p</i> = 0.046) were associated with inferior OS. We concluded that hypoalbuminemia confers poor prognosis in ES spine. Survival outcomes are poorer in females treated in our setting, possibly due to prevailing sex-based biases.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2023.2296949","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Ewing sarcoma (ES) of the spine is a rare childhood cancer with sparse literature on treatment outcomes. We aimed to describe survival outcomes and prognostic factors in patients with spinal ES treated at a single institute in a resource-challenged setting. We conducted a retrospective analysis of patients with spinal ES registered at a tertiary care oncology center between 2003-2019. Clinical patient data was retrieved from hospital records. Cox regression analysis was used to identify the association of baseline clinical parameters with event free survival (EFS) and overall survival (OS). A cohort of 85 patients was analyzed including 38 (45%) patients with metastatic disease. The median age was 15 years with 73% being male. Local therapy was administered in 62 (72.9%) patients with surgery alone in 8 (9.4%), radiotherapy alone in 36 (42.4%) and both in 18 (21.2%) patients. A higher proportion of males received local therapy than females (80.3% versus 59.1%; p = 0.049). The median EFS and OS were 20.1 and 28.6 months, respectively. On univariable analysis, age ≤ 15 years, female sex, serum albumin ≤3.5 g/dL and hemoglobin ≤11 g/dL were associated with inferior EFS while younger age, female sex, hypoalbuminemia and metastatic disease were associated with inferior OS. On multivariable analysis, only hypoalbuminemia was predictive for inferior EFS (HR:2.41; p = 0.005) while hypoalbuminemia (HR:2.06;p = 0.033) and female sex (HR:1.83; p = 0.046) were associated with inferior OS. We concluded that hypoalbuminemia confers poor prognosis in ES spine. Survival outcomes are poorer in females treated in our setting, possibly due to prevailing sex-based biases.
脊柱尤文肉瘤(ES)是一种罕见的儿童癌症,有关治疗效果的文献很少。我们的目的是描述在资源有限的情况下在一家机构接受治疗的脊柱ES患者的生存结果和预后因素。我们对 2003-2019 年间在一家三级肿瘤中心登记的脊柱 ES 患者进行了回顾性分析。临床患者数据来自医院病历。Cox回归分析用于确定基线临床参数与无事件生存期(EFS)和总生存期(OS)的关系。共分析了 85 例患者,其中包括 38 例(45%)转移性疾病患者。中位年龄为15岁,73%为男性。62名(72.9%)患者接受了局部治疗,其中8名(9.4%)患者仅接受了手术治疗,36名(42.4%)患者仅接受了放射治疗,18名(21.2%)患者同时接受了两种治疗。接受局部治疗的男性比例高于女性(80.3% 对 59.1%;P = 0.049)。中位生存期和生存期分别为20.1个月和28.6个月。在单变量分析中,年龄≤15岁、女性、血清白蛋白≤3.5 g/dL和血红蛋白≤11 g/dL与较差的EFS相关,而年龄较小、女性、低白蛋白血症和转移性疾病与较差的OS相关。在多变量分析中,只有低白蛋白血症可预测较差的 EFS(HR:2.41; p = 0.005),而低白蛋白血症(HR:2.06; p = 0.033)和女性性别(HR:1.83; p = 0.046)与较差的 OS 相关。我们的结论是,低白蛋白血症会导致 ES 脊椎预后不良。在我们的病例中,女性患者的生存率较低,这可能是由于普遍存在的性别偏见。
期刊介绍:
PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.